Once-weekly risedronate in men with osteoporosis: Results of a 2-Year, placebo-controlled, double-blind, multicenter study

Journal of Bone and Mineral Research

Volumn 24, Issue 4, 2009, Pages 719-725

  Boonen, Steven ^a   Orwoll, Eric S ^b   Wenderoth, Dietrich ^c   Stoner, Karen J ^c   Eusebio, Rachelle ^d   Delmas, Pierre D ^e  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PROCTER AND GAMBLE COMPANY   (United States)

^d PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^e UNIVERSITÉ DE LYON   (France)

Author keywords

Bisphosphonate; BMD; Bone turnover; Male osteoporosis; Risedronate

Indexed keywords

CALCIUM; PLACEBO; RISEDRONIC ACID; VITAMIN D;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BONE TURNOVER; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMUR NECK; FRACTURE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFLUENZA; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOPOROSIS; PAIN; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK REDUCTION; VERTEBRA FRACTURE;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; HUMANS; LEAST-SQUARES ANALYSIS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; PLACEBOS; TREATMENT OUTCOME;

EID: 65549099590     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.081214     Document Type: Article

References (23)

1. Cooper C, Campion G, Melton LJ III 1996 Hip fractures in the elderly: A world-wide projection. Osteoporos Int 2:285-289.
2. Seeman E 2009 International Osteoporosis Foundation Committee of Scientific Advisors Invest In Your Bones-Osteoporosis in men: The 'silent epidemic' strikes men too. Available online at: http://www.iofbonehealth.org/ download/osteofound/filemanager/publications/pdf/osteoporosis-in-men. pdf. Accessed June 5 2008.
3. Singer BR, McLauchlan GJ, Robinson CM, Christie J 1998 Epidemiology of fractures in 15,000 adults: The influence of age and gender. J Bone Joint Surg Br 80:243-248.
4. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA 1999 Mortality after all major types of osteoporotic fracture in men and women: An observational study. Lancet 353: 878-882.
5. Forsèn L, Søgaard AJ, Meyer HE, Edna T, Kopjar B 1999 Survival after hip fracture: Short- and long-term excess mortality according to age and gender. Osteoporos Int 10:73-78.
6. Johnell O, Kanis J, Gullberg G 2001 Mortality, morbidity, and assessment of fracture risk in male osteoporosis. Calcif Tissue Int 69:182-184.
7. Amin S, Felson DT 2001 Osteoporosis in men. Rheum Dis Clin North Am 27:19-47.
8. Campion JM, Maricic MJ 2003 Osteoporosis in men. Am Fam Physician 67:1521-1526.
9. Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ 1998 Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including ras. J Bone Miner Res 13:581-589.
10. Harris ST, Watts NB, Genant HK, McKeever CD. Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344- 1352.
11. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos lnt 11:83-91.
12. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333-340.
13. Reid DM, Adami S, Devogelaer J-P, Chines AA 2001 Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 69:242-247.
14. Siminoski K, Leslie WD, Frame H, Hodsman A, Josse RG, Khan A, Lentle BC, Lèvesque J, Lyons DJ, Tarulli G, Brown JP for the Canadian Association of Radiologists 2005 Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J 56:178-188.
15. Brown JP, Josse RG 2002 Scientific Advisory Council of the Osteoporosis Society of Canada 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167(Suppl):Sl-S34.
16. Kanis JA, Johnell O, Oden A, De Laet C, Mellström D 2001 Diagnosis of osteoporosis and fracture threshold in men. Calcif Tissue lnt 69:218-221.
17. Orwoll E 2000 Assessing bone density in men. J Bone Miner Res 15:1867-1870.
18. Genant HK, Wu CY, van Kuijk C, Nevitt MC 1993 Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148.
19. Eastell R, Barton I. Hannon RA, Chines A. Garnero P, Delmas PD 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051-1056.
20. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A 2000 Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604-610.
21. Ringe JD, Faber H, Farahmand P, Dorst A 2006 Efficacy of risedronate in men with primary and secondary osteoporosis: Results of a 1-year study. Rheumatol Int 26:427-431.
22. Ringe JD, Dorst A. Faber H 2005 Consistent 60% risk reduction of new vertebral fractures in men with osteoporosis after the first and second year of risedronate therapy. J Bone Miner Res 20:S1;S279.
23. Sato Y, Iwamoto J, Kanoko T, Satoh K 2005 Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 165:1743-1748.